{"filings":[{"id":190623,"accession_number":"0001096906-24-002002","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.01","5.02"],"status":"ready","headline":"Change in control at AXIM Biotechnologies; CEO John Huemoeller dies, Catalina Valencia named President","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kettner Investments acquires control via Series C Preferred Stock transfer from Juniper & Ivy and Medical Marijuana, Inc.","CEO/President John W. Huemoeller II died Oct 12 due to illness; board appointed Catalina Valencia as President on Oct 9.","Valencia also appointed Series C Director to fill vacancy from Huemoeller's death; she previously founded Sapphire Biotech.","Series C stock transferred from Juniper to MJNA to satisfy $515K note, then to Kettner to waive $1.09M notes plus $66K interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243768,"accession_number":"0001096906-24-000539","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AXIM issues $814,555 in convertible notes and restricted stock for past-due compensation","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $814,555 convertible notes to directors, officers, contractors, and Sapphire employees to settle past salaries/fees.","Notes carry 4.25% annual interest, mature March 1, 2034; three versions with conversion prices of $0.01 or $0.02.","Also sold 1,100,000 restricted shares at $0.01 per share to a Sapphire employee for $11,000 of past-due salary.","Full conversion of all notes yields 47,727,750 common shares; conversion blocked until stock trades at $0.20 for 30 days after 6 months.","Notes are non-transferable; 25% principal due annually for Version 1 Notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243767,"accession_number":"0001096906-24-000199","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"AXIM Biotechnologies settles IMS litigation; to issue 20M restricted shares plus cash and royalties","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Innovative Medical Supplies resolves two lawsuits; no admission of wrongdoing.","Cash payment of $100,000 payable over 24 months.","Royalty of $0.35 per dry eye test cassette sold, capped at $475,000 total.","Issues 20M restricted shares; 12-month lock-up, then drip-out limit of 1% of outstanding per 90 days.","Shares issued under Section 4(a)(2) of Securities Act; unregistered sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261177,"accession_number":"0001096906-23-002456","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Axim Biotech enters up to $750K convertible note deal with affiliate Medical Marijuana Inc","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $100,000 note issued Dec 26, 2023; MJNA can purchase up to $750,000 total by June 26, 2025.","Notes bear 5.25% interest, mature Dec 26, 2033; interest payable annually starting Dec 26, 2024.","Conversion price is lesser of $0.01 or 70% of avg two lowest closing prices in prior 10 trading days.","Conversion capped at 4.9% beneficial ownership; notes sold unregistered under Regulation D.","Proceeds for working capital, product development, and clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296601,"accession_number":"0001096906-23-001228","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"AXIM Biotechnologies enters $20M equity purchase agreement with Cross & Company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity Purchase Agreement for up to $20M of common stock with an institutional investor (Cross & Company).","Company may require investor to buy shares in puts of $10k-$250k, subject to volume limits.","Purchase price set at 87.5% of lowest traded price during a 10-day valuation period after clearing.","Agreement term up to 3 years; registration statement on Form S-1 required for resale of put shares.","Issuance capped at 4.99% beneficial ownership; dilution potential from discounted share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296600,"accession_number":"0001096906-23-001206","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AXIM Biotechnologies issues $575K in convertible notes with 3.75% interest and variable conversion price","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal of $575,000: $325,000 cash from four notes, $250,000 to repay prior advances.","Interest rate 3.75% per annum, payable annually starting May 23, 2024; maturity May 23, 2033.","Conversion price is lesser of $0.01 or 70% of average of two lowest closing prices in prior 10 trading days.","Notes are unsecured; no prepayment without holder consent; includes 4.9% beneficial ownership blocker.","Event of default allows holder to accelerate all principal and accrued interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296599,"accession_number":"0001096906-23-001188","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AXIM Biotechnologies appoints Kurt Phinney as COO; grants option for 2M shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kurt Phinney appointed COO effective May 23, 2023; minimum six-month term.","Compensation: option to buy up to 2,000,000 shares (S-8), vesting 1/6 every 30 days.","Phinney's prior roles include VP Ops at Lumos Diagnostics and Versea Health.","Consulting agreement with Accalle, LLC (Phinney's entity); no cash salary.","Agreement may be terminated after initial term with 30 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317027,"accession_number":"0001096906-23-000219","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2023-01-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"AXIM cures defaults on $5.3M in debt, cuts conversion prices, gives CEO $250K note for back pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TL-66 waives $216,572 interest on $934,478 secured notes; conversion price cut to $0.04 from $0.2201.","MMI waives $261,537 interest on $4M note; conversion price cut to $0.075 from $0.25.","CEO forgives $50K of $512.5K back salary; gets $250K note at $0.01; $212.5K deferred to July 1, 2023.","CEO salary cut by $55,000 for H1 2023 to preserve working capital.","Additional interest waivers on TL-66 ($11,191) and Sapphire ($17,116) notes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352710,"accession_number":"0001096906-22-002280","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2022-09-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AXIM signs exclusive global licensing deal with Verséa for dry eye diagnostic tests","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five-year License and Distribution Agreement with Verséa for global sale of AXIM's point-of-care ocular diagnostics.","Three tests included: IgE (allergy), Lactoferrin (dry eye), and MMP-9 (inflammation); IgE and Lactoferrin are FDA-cleared.","Verséa plans to launch IgE and Lactoferrin tests at 2022 AAO and Optometry conferences; MMP-9 in 18–24 months.","Verséa must meet annual minimum sales commitments; no upfront or milestone payments disclosed.","CEO Huemoeller says deal marks transition from development-stage to revenue-generating healthcare organization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352709,"accession_number":"0001096906-22-002035","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2022-08-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"AXIM issues 13.86M restricted shares in two private placements for $350K total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,861,004 restricted shares to affiliate Catalina Valencia for $100,000 ($0.0259/share).","Issued 10,000,000 restricted shares to Versea Holdings for $250,000 ($0.025/share).","Both issuances completed on August 29, 2022; shares sold under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389399,"accession_number":"0001096906-22-000524","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["1.02","7.01","9.01"],"status":"ready","headline":"AXIM shifts COVID-19 NAb test to RUO; separates from Empowered Diagnostics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["COVID-19 NAb test now offered For Research Use Only after FDA changed priorities from qualitative testing.","Entered separation agreement with Empowered Diagnostics, LLC following FDA recall of their products.","Two RUO tests available: quantitative (exact number) and semi-quantitative (high/medium/low titers).","Partner Dr. Lake conducting ongoing correlative study at ASU on vaccine vs natural immunity NAb levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389398,"accession_number":"0001096906-22-000353","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"AXIM raises $1.825M in new debt; retires $1.11M GS Capital note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued two $250K short-term notes (1.5% interest, due March 10, 2022); one repaid on Feb 14.","Issued seven convertible notes aggregate $1.325M at 3% interest, due 2032; conversion at 70% of avg two lowest closing prices.","One $25K convertible note was acquired by director Blake N. Schroeder.","Repaid GS Capital Partners note ($1.11M face) in full; accrued interest $21,876 paid via 173,390 restricted shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389397,"accession_number":"0001096906-22-000092","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2022-01-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AXIM appoints Blake N. Schroeder as director to fill vacancy, effective Jan 6, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Schroeder replaces Mauricio Javier Gatto-Bellora, appointed by written consent of Series C preferred stockholder.","Schroeder serves as CEO and Chairman of Medical Marijuana, Inc., which holds ~16.4% of AXIM common stock.","He formerly served as COO of Forevergreen International and held roles at MonaVie; holds a J.D. and B.S. in Finance.","No related-party transactions or arrangements exist between Schroeder and AXIM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389396,"accession_number":"0001096906-22-000068","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2022-01-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"AXIM Biotechnologies director Mauricio Gatto Bellora resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mauricio Gatto Bellora resigned from the Board of Directors effective January 4, 2022.","Resignation was accepted by the Company on January 4, 2022.","Mr. Bellora's departure was not due to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426331,"accession_number":"0001096906-21-001784","cik":1514946,"company_name":"AXIM BIOTECHNOLOGIES, INC.","ticker":"AXIM","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"AXIM Biotech signs binding term sheet to acquire FDA-cleared dry eye tests, paying 7M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["AXIM to acquire two FDA-cleared dry eye diagnostic tests from Advanced Tear Diagnostics for 7M restricted shares.","Tests include 10-minute lactoferrin assay and ocular IgE test; commercial launch targeted for early 2022.","Dry eye disease affects ~20M in US; global DED diagnostics market projected at $9.8B by 2030.","Binding term sheet in effect; definitive agreement and closing expected by October 1, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1906557.333333333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}